We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Combining Amino Acid PET and MRI Imaging to Help Treat Aggressive Brain Tumors

By MedImaging International staff writers
Posted on 31 Oct 2023
Print article
Image: The new PET scan procedure allows for more precise localization of brain tumors (Photo courtesy of Lukaszczyk Oncology Center)
Image: The new PET scan procedure allows for more precise localization of brain tumors (Photo courtesy of Lukaszczyk Oncology Center)

For achieving the best results in removing brain tumors, neurosurgeons and radiation oncologists need to be extremely accurate in locating the spread of glioma cells within the brain tissue of a patient. Currently, the primary method for obtaining this essential information is through nuclear magnetic resonance imaging or MRI. During surgery, neurosurgeons rely on MRI images to determine the extent of the cancerous lesion to be removed. In radiotherapy, a standard safety margin of about two centimeters beyond the visible tumor edges is typically used. Now, a new tumor imaging process that employs positron emission tomography (PET) could offer a more refined approach to the precise removal of brain tumors.

Collaborative efforts undertaken by healthcare and scientific institutions including Franciszek Lukaszczyk Oncology Center (Bydgoszcz, Poland) have led to the development of a new glioblastoma imaging procedure. The PET imaging starts with administering a safe dose of a rapidly decaying radioisotope, fluorine-18, to the patient. This radioisotope is then integrated into tyrosine molecules, an amino acid that is more abundant in cancer cells than in healthy brain tissue. When the tyrosine molecule is within the tumor and the radioisotope atom decays, a positron—a positively charged antiparticle of an electron—is emitted.

As the human body is rich in electrons, this positron quickly comes into contact with an electron, resulting in mutual destruction and the conversion of their mass into energy. This event produces two photons with different energies that travel in opposite directions. A PET scanner detects these emitted photons and, by measuring the differences in their arrival times, identifies the exact point where the annihilation occurred. This process serves as a dependable method for pinpointing the location of tumor cells.

“In the course of our study, we have demonstrated our ability to assess high-grade glioma infiltration beyond the observable boundaries provided by contrast-enhancement in magnetic resonance imaging,” said Prof. Maciej Harat, one of the architects of the research framework. “This suggests that even the most aggressive tumor resection guided by MRI imaging may inadvertently leave a significant portion of the tumor unaddressed, consequently precipitating rapid disease recurrence. This discovery is a direct outcome of our principal achievement, namely, the validation of an alternative brain imaging modality: positron emission tomography utilizing fluorine-labeled tyrosine.”

Related Links:
Franciszek Lukaszczyk Oncology Center

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Ultrasound System
P20 Elite
New
Enterprise Imaging & Reporting Solution
Syngo Carbon
Ultrasound System
Acclarix AX9

Print article

Channels

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.